Robotic Surgery And Digital Health Will Shape Leadership In Global Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

18 Jul 24

Updated

08 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

21.2%

7D

-2.7%

Loading

1Y

21.2%

7D

-2.7%

You can edit this narrative until Dec 9 12:05 PM. Then, changes will post as Updates.

Author's Valuation

US$111.0511.2% undervalued

AnalystConsensusTarget Fair Value

Shared on 08 Dec 25

Fair value Increased 1.12%

MDT: Future Performance Will Reflect Cardiovascular Momentum And Emerging Product Execution Risks

Analysts have nudged our Medtronic fair value estimate higher to $111.05 from $109.82, reflecting a wave of price target increases following better than expected Q2 sales and EPS, confidence in mid single digit plus organic growth, and strengthening new product and cardiovascular momentum. Analyst Commentary Street research following the Q2 print has turned more constructive on Medtronic, with a cluster of price target increases and at least one notable rating upgrade framing the debate around the durability of mid single digit plus organic growth and improving execution.

Shared on 24 Nov 25

Fair value Increased 8.59%

MDT: Expect Future Performance To Reflect New Products And Evolving Corporate Focus

Medtronic's fair value estimate has been raised from $101.13 to $109.82 per share. This reflects analysts' view that accelerating sales growth, improved guidance, and sustained operational progress support a higher valuation.

Shared on 08 Nov 25

MDT: Focus Will Shift To Board Changes And New Committee Impact

Medtronic's analyst price target has recently increased, with updated targets rising as high as $115. This reflects analysts' growing optimism about the company due to anticipated revenue growth, positive investor engagement, and confidence in its product pipeline and execution.

Shared on 24 Oct 25

Fair value Increased 1.23%

Medtronic's analyst price target has risen modestly, increasing from approximately $99.90 to $101.13. Analysts cite healthy expectations for upcoming quarterly results and improving sentiment in the medical technology sector.

Shared on 10 Oct 25

Fair value Increased 1.29%

Medtronic's analyst price target has increased slightly to approximately $99.90, as analysts cite improved sector sentiment, recent company developments, and opportunities identified in Medtronic's product pipeline and market positioning. Analyst Commentary Recent research notes have shown a mixture of optimism and caution regarding Medtronic's outlook.

Shared on 27 Aug 25

Fair value Increased 1.30%

Analysts have raised Medtronic’s price target to $98.44, citing activist involvement, operational improvements, and favorable policy developments, though some concerns about execution remain. Analyst Commentary Bullish analysts have raised price targets on expectations that Elliott Management's active involvement and the addition of independent directors will sharpen Medtronic's strategic focus and drive stronger growth initiatives.

Shared on 07 May 25

Fair value Decreased 0.54%

Shared on 30 Apr 25

Fair value Increased 1.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 0.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 11%

AnalystConsensusTarget has increased future PE multiple from 22.8x to 25.4x.

Shared on 10 Mar 25

Fair value Decreased 8.96%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$111.05

11.2% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

5.44%

Medical Equipment revenue growth rate

8.17%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.75%

Calculation

US$6.46b

Earnings '28

x

28.31x

PE Ratio '28

=

US$183.04b

Market Cap '28

US$183.04b

Market Cap '28

/

1.28b

No. shares '28

=

US$142.87

Share Price '28

US$142.87 Share Price '28

Discounted to 2025 @ 8.77% p.a.

=

US$111.03

Fair Value '25